You’ve got a great idea. Now what?

It takes years of trial and error to move an ophthalmology product from concept to commercialization. But when you believe your technology could “change the future of cataract surgery,” you’ve got the motivation you need to keep moving forward. 

After nearly a dozen prototypes, Lexington, Kentucky-based Gary Wortz, MD, Chief Medical Officer of Omega Ophthalmics, has a product that’s producing strong data in early research. 

The Gemini Refractive Capsule reduces variables in the predictive effect of intraocular intraocular lens implants. The technology fits inside the natural capsular bag once the surgeon removes the cortex. The lens capsule, Dr. Wortz says, is the safest place to implant a medical device because the area has no nerve endings or blood vessels. The technology helps reduce posterior capsular opacification and stunts fibrosis.

To date, Dr. Wortz says Omega Ophthalmics has about 100 devices implanted that are well tolerated. The company is currently evaluating next steps.

Tune in now to listen to the conversation between colleague and friend Paul Karpecki, MD, and Dr. Wortz. You’ll discover:

·         The implementation process for the Omega Gemini Refractive Capsule and the advantages of using “the most important real estate in the body.”

·         How Gary balances his medical practice, entrepreneurial endeavors, family life, and personal time. Hint: learn the art of “no.”

·         What he learned through nurturing a product to fruition: from the idea, through the “messy middle,” to commercialization.

·         How Omega Ophthalmics raised funds without venture capital.